Socazolimab (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary,...
Indian Institute of Chemical Technology, (IICT), a constituent laboratory of CSIR and Lee Pharma, an integrated pharmaceutical company based in Hyderabad, have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG).
Hyderabad-based Indian Institute of Chemical Technology, a constituent laboratory of Council of Scientific and Industrial Research (CSIR-IICT,) and pharmaceutical company Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG).
Hyderabad-based Indian Institute of Chemical Technology, a constituent laboratory of Council of Scientific and Industrial Research (CSIR-IICT,) and pharmaceutical company Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG).
SAN DIEGO, March 07, 2021 (GLOBE NEWSWIRE) -- China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharm, HKEX: 950) announced that its anti-PD-L1 antibody, Socazolimab, licensed from Sorrento to COF for the greater China territory, has been cleared to begin a multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. The clearance is based on the results from an earlier Phase Ib trial in which Socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile in patients with extensive-stage small-cell lung cancer. The Principal Investigator for the clinical trial will be Professor Shun Lu from the Shanghai Chest Hospital and the site is expected to initiate patient recruitment in the second quarter of 2021.
The deal gives Lee's Pharm exclusive rights to develop and commercialize GC's anticoagulant candidate drug for the greater China and South East Asian market
Two Indian drugmakers said they had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma.
SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has enrolled the first U.S. patient in its ongoing multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC). The trial is evaluating the use of Pexa-Vec to treat HCC patients who have failed locoregional therapies and are eligible for treatment with sorafenib (Nexavar®), the only approved drug for advanced HCC. The U.S. patient was enrolled at the University of Tennessee Medical Center in Knoxville, Tennessee.